ANAPTYSBIO INC. - COM

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

25 окт 2021 15:37:00 Источник Nasdaq GlobeNewswire

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

02 окт 2021 11:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 сен 2021 15:05:00 Источник Nasdaq GlobeNewswire

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

17 авг 2021 15:32:07 Источник Nasdaq GlobeNewswire

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

27 май 2021 15:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

04 май 2021 15:05:01 Источник Nasdaq GlobeNewswire

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

23 апр 2021 09:31:07 Источник Nasdaq GlobeNewswire

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

22 апр 2021 15:12:22 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

12 апр 2021 15:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

25 фев 2021 15:05:01 Источник Nasdaq GlobeNewswire

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

07 янв 2021 15:15:00 Источник Nasdaq GlobeNewswire